Comorbidity

New Research Demonstrates Clinical Effectiveness of Digital Treatment at Improving Insomnia and Comorbid Mental and Physical Health Issues

Retrieved on: 
星期一, 十月 9, 2023
Page, Doctor of Philosophy, Anxiety, Cognitive behavioral therapy, Cerebrovascular disease, Sleep, Sleep medicine, Nation, Therapy, Psychology, Ageing, University, Dave's Picks Volume 38, Digital, Comorbidity, Disease, Cancer, Randomized controlled trial, Brain damage, Spectrum, Insomnia, Meta-analysis, DSM-IV codes, Journal of Affective Disorders, Research, Depression, SAN, Survivor, RCT, CBT, Nuffield Department of Population Health, ASCO, WSO, PMID, Disability, Systematic review, Canadian International Council, PMCID, Neurorehabilitation and Neural Repair, University of Oxford, Patient, Pharmaceutical industry, Nursing, Dietary supplement, Sleepio, Stroke

SAN FRANCISCO and OXFORD, England, Oct. 9, 2023 /PRNewswire-PRWeb/ -- Big Health, the leader in digital therapeutics for the most common mental health conditions, announced today the publication of two, peer-reviewed studies demonstrating the effects of its flagship digital insomnia treatment Sleepio in individuals with co-morbid insomnia and clinically significant anxiety as well as in stroke survivors. 

Key Points: 
  • Digital cognitive behavioral therapy (dCBT) has long been evidenced as an effective treatment for insomnia and anxiety — key findings from these studies provide new insights into Sleepio's impact.
  • In a separate study among stroke survivors, 71% achieved remission using Sleepio compared to 30% of control participants.
  • Individuals with insomnia are three times more likely to develop anxiety than healthy sleepers.
  • [1] Additionally, comorbid insomnia and anxiety are associated with greater severity of both conditions — as well as increased symptoms of depression and poorer physical health.

Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Month

Retrieved on: 
星期三, 十月 4, 2023
Therapy, ASTRO, RECIST, Cancer, Progression-free survival, Head, NANO, Cisplatin, Radiation therapy, Neck, Sepsis, CRR, Death, Radiation, MD, Patient, Lymph, Comorbidity, HNSCC, Webcast, Observation, Nanobiotix, IMRT, Ageing, Neoplasm, MOS, Principal, RT, NBTXR3, Society, ACCI, ORR, Safety, Pharmaceutical industry, Euronext

During the call, Laurent Levy, chief executive officer, will review the Study 102 final data before taking questions from participants.

Key Points: 
  • During the call, Laurent Levy, chief executive officer, will review the Study 102 final data before taking questions from participants.
  • Surgery or definitive cisplatin-based chemotherapy are the current standard of care for patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC; head and neck cancer).
  • One third of these patients, however, cannot tolerate cisplatin due to complications such as age-related frailty or other medical conditions (comorbidities).
  • At the final readout, an independent review committee determined a median Progression-Free Survival (mPFS) of 16.9 months in evaluable patients.

Spring Health expands its substance use disorder services with new Eleanor Health partnership

Retrieved on: 
星期四, 九月 28, 2023
SUD, Health, Entrepreneurship, Partnership, Research, Mental health, Comorbidity, Element, Pharmaceutical industry, Nursing

NEW YORK, Sept. 28, 2023 /PRNewswire/ -- Spring Health, the most comprehensive global mental health solution for employers and health plans, today announced a significant expansion of its substance use disorder (SUD) support services through a new partnership with Eleanor Health, a leading provider of in-person and virtual care for addiction and substance use disorders.

Key Points: 
  • Spring Health offers the only integrated mental health solution on the market for every level of support for substance use disorder.
  • NEW YORK, Sept. 28, 2023 /PRNewswire/ -- Spring Health, the most comprehensive global mental health solution for employers and health plans, today announced a significant expansion of its substance use disorder (SUD) support services through a new partnership with Eleanor Health, a leading provider of in-person and virtual care for addiction and substance use disorders.
  • Spring Health has partnered with Eleanor Health to ensure that all members can receive tailored care that addresses the entirety of their mental health support needs related to SUD.
  • "By expanding our substance use disorder program with Eleanor, we are providing another important modality for specialized care that meets each member where they are in their mental health and addiction journey," said April Koh, CEO and Co-Founder of Spring Health.

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Retrieved on: 
星期二, 九月 19, 2023
Blood pressure, HTN, Orchestra, MDT, Institutional review board, Freedom, Press release, HOPE, OSBP, Division, Beat (music), Treatment, GA, Bradycardia, Cardiac electrophysiology, Cooper University Hospital, Patient, Collection, Video news release, Comorbidity, Risk, Physician, CNT, Webcast, IDE, FDA, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, NYSE, Food, Pharmaceutical industry, Medical device, Medtronic, Cardiology, Hypertension

Orchestra BioMed and Medtronic plc (NYSE: MDT) formed a strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker patients in July 2022.

Key Points: 
  • Orchestra BioMed and Medtronic plc (NYSE: MDT) formed a strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker patients in July 2022.
  • Under the collaboration, Medtronic is providing Orchestra BioMed with development, clinical, and regulatory support for the BACKBEAT global pivotal study, which Orchestra BioMed is sponsoring.
  • Orchestra BioMed will share in the revenues generated from Medtronic sales of the AVIM-enabled pacing systems.
  • “We are thrilled to receive IDE approval from the FDA and move forward with plans to initiate the BACKBEAT global pivotal study, which is designed to support potential future regulatory review and potential approval of AVIM therapy for hypertensive patients indicated for a pacemaker.

Venous Thromboembolism (VTE) Epidemiology Forecasts, 2032 - Overview of the Risk Factors, comorbidities, and Global & Historical Trends

Retrieved on: 
星期一, 八月 14, 2023
AGR, VTE, PE, Therapy, Chronic kidney disease, Coronary thrombosis, Atrial fibrillation, DVT, Cancer, Risk, Incidence, Publishing, Patient, Comorbidity, Epidemiology, CKD, Dietary supplement, Pharmaceutical industry

DUBLIN, Aug. 14, 2023 /PRNewswire/ -- The "Venous Thromboembolism (VTE) Epidemiology Analysis and Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 14, 2023 /PRNewswire/ -- The "Venous Thromboembolism (VTE) Epidemiology Analysis and Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.
  • The number of VTE attacks is forecast to grow from 1,602,747 in 2022, to 1,848,622 in 2032 in the 7MM, at an AGR of 1.53%.
  • The publishing epidemiologists also forecast the number of medically ill patients at risk for VTE to increase in the 7MM from 38,508,614 in 2022 to 41,825,735 in 2032.
  • This report provides an overview of the risk factors, comorbidities, and the global and historical trends for VTE in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

Alera Health Partners With Integral Health Network of Southern Arizona (IHNSA) to Assume Clinical and Fiscal Responsibility For 8,000 Banner - University Health Plans Members Diagnosed with Comorbid Medical and Behavioral Health Conditions

Retrieved on: 
星期四, 八月 3, 2023
Association for Community Affiliated Plans, UHP, Banner Health, Medicaid, Operation HOPE, Inc., Partnership, Housing, Windows Live, OneTouch Ultra, Integrated care, Parent, Population Health Management, APM, Lake of the Ozarks Community Bridge, Comorbidity, Patient, Frontera, Recovery, Health, Psychiatry, Wellness, Accountable care organization, Health insurance, Nursing, Medicare

TUCSON, Ariz., Aug. 3, 2023 /PRNewswire/ -- Alera Health, in partnership with The Integral Health Network of Southern Arizona, LLC (IHNSA), a high-performance network of integrated behavioral health, medical, and social care providers, today announced the launch of a new Alternative Payment Model (APM) with Banner – University Health Plans (B – UHP) that will connect members with acute and chronic behavioral health conditions with IHNSA's integrated system of care. This innovative model of integrating primary, behavioral, and social care aims to engage members with complex care needs, improve the holistic well-being of those members, and lower the total cost of care for health plans.

Key Points: 
  • Comorbid behavioral health and physical health illness accelerates disease trajectory and cost payers, managed care organizations, and accountable care organizations 3.5 times more than solitary conditions.
  • Integral Health Network of Southern Arizona, LLC (IHNSA) was organized as a clinically integrated network in 2021 to provide integrated, coordinated care for patients suffering from primary and secondary behavioral health conditions and living in southern Arizona.
  • Banner – University Health Plans (B – UHP) is a locally owned health plan and is a recognized Medicaid managed care leader.
  • B – UHP owns and operates: Banner – University Family Care/ACC, Banner – University Family Care/ALTCS, and Banner Medicare Advantage and includes more than 340,000 lives in Arizona.

Biophytis: Biophytis has requested a pre-submission meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the treatment of COVID-19

Retrieved on: 
星期四, 七月 20, 2023
EUA, Emergency Use Authorization, Euronext Growth, CET, Therapy, Comorbidity, COVID-19, Pathology, Ageing, Treatment and management of COVID-19, EMA, European Medicines Agency, Death, Food and Drug Administration, Patient, Risk, WHO, Immunodeficiency, FDA, Notifiable disease, Food, Respiratory failure, Pharmaceutical industry

Stanislas Veillet, Chief Executive Officer of Biophytis, commented: “We are actively pursuing our roadmap by initiating discussions with the FDA to bring our drug candidate to patients suffering from severe forms of COVID-19 in the United States.

Key Points: 
  • Stanislas Veillet, Chief Executive Officer of Biophytis, commented: “We are actively pursuing our roadmap by initiating discussions with the FDA to bring our drug candidate to patients suffering from severe forms of COVID-19 in the United States.
  • Like influenza, this pathology has become an endemic respiratory infectious disease that can lead to Acute Respiratory Distress Syndrome (ARDS) in elderly, immunocompromised or co-morbid patients.
  • According to the WHO, the medical need remains high, with several thousand deaths per week in the United States and Europe.
  • We look forward to starting discussions with the FDA, and depending on feedback from this agency, we could consider filing an Emergency Use Application by the end of 2023 or in the first half of 2024."

Compile Expands Access to Real World Data for Life Sciences Companies with Novel Complete Claims Dataset

Retrieved on: 
星期三, 七月 19, 2023
Medicaid, National Provider Identifier, History, Netgear, Forecasting, NPI, Data, Patient, Comorbidity, Commercial, Rare, Compiler, Economics, Pharmaceutical industry, Health insurance, Medicare, Individual

MENLO PARK, Calif., July 19, 2023 /PRNewswire/ -- Compile, a novel provider of life sciences data products, today announced the launch of Multi-Payer Complete Claims ReadyData, a dataset which will allows life sciences and biotech companies to conduct more granular analyses, leading to more optimized drug commercialization and reimbursement strategies.

Key Points: 
  • MENLO PARK, Calif., July 19, 2023 /PRNewswire/ -- Compile , a novel provider of life sciences data products, today announced the launch of Multi-Payer Complete Claims ReadyData, a dataset which will allows life sciences and biotech companies to conduct more granular analyses, leading to more optimized drug commercialization and reimbursement strategies.
  • "Multi-Payer Complete Claims ReadyData provides life sciences companies with this visibility, empowering them to do better, more granular analyses, and take steps to improve patients' financial access to drugs."
  • Complete or "closed" claims data provides full capture of all claims for members covered under certain plans, for a more complete view of a patient's healthcare activities during a specific period.
  • Multi-Payer Complete Claims ReadyData is the fourth in Compile's suite of data products, which include Open Claims ReadyData, All Medicare Complete Claims ReadyData, and Provider 360 ReadyData.

EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023

Retrieved on: 
星期三, 七月 12, 2023
PMID, Huber loss, Onset, Brain, Comorbidity, The Different Forms of Flowers on Plants of the Same Species, Eisai, MRI, Pharmacokinetics, PLOS One, Co-promotion, Immunogenicity, Medical imaging, Pharmaceutical industry, Alzheimer's disease, Safety

This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety.

Key Points: 
  • This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety.
  • There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.
  • Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, Lannfelt L, Pettersson FE.
  • Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.

New Study Finds At Least Twice as Many US Adults Experience Schizophrenia Spectrum Disorders Than Previously Thought

Retrieved on: 
星期二, 六月 27, 2023
Columbia University, Prison, Structured Clinical Interview for DSM, Duke University, Substance Abuse, Spectrum, University, Prevalence, Life, Harvard University, Schizophrenia, Disability, Schizophreniform disorder, SAMHSA, Treatment Advocacy Center, Diagnosis, Substance Abuse and Mental Health Services Administration, Schizoaffective disorder, DSM-IV codes, Research, Life expectancy, RTI, Mental, New York State Psychiatric Institute, RESEARCH, Fifth Edition, Comorbidity, University of Washington School of Medicine, DSM-5, Health, Mental health, PARK, RTI International, Pharmaceutical industry, Nursing, Dietary supplement

Schizophrenia spectrum disorders include schizophrenia, schizoaffective disorder and schizophreniform disorder.

Key Points: 
  • Schizophrenia spectrum disorders include schizophrenia, schizoaffective disorder and schizophreniform disorder.
  • "The MDPS finding that schizophrenia spectrum disorders may be more prevalent than previously thought is especially important," said Heather Ringeisen , Ph.D., vice president, health of populations at RTI and principal investigator of the project.
  • "People with a schizophrenia spectrum disorder experience high levels of disability that present significant challenges in all aspects of their life."
  • Treatments for schizophrenia spectrum disorders exist but not all people who are diagnosed receive effective treatment.